Skip to main content English


Karsten Bamminger
Karsten Bamminger, MSc

Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine)
Position: PHD Student

ORCID: 0000-0003-3811-7485


Biomarkers, Pharmacological; Positron-Emission Tomography; Programmed Cell Death 1 Receptor

Research interests

My research focuses primarily on the development of PET tracers for the PD-1/PD-L1 immune checkpoint. The ultimate goal is to achieve a better patient stratifcation in the context of anti-cancer immunotherapy and to improve therapy respone and survial.

Selected publications

  1. Bamminger, K. et al. (2022) ‘Rapid, high-yield enzymatic synthesis of n.c.a. 6-[18F]fluorodopamine (6-[18F]FDA) for in vivo application’, Nuclear Medicine and Biology [Preprint]. Available at:
  2. Pichler, V. et al., 2019. Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharmacy and Chemistry, 4(1). Available at:
  3. Tournier, N. et al. (2019) ‘Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans’, Journal of Nuclear Medicine, 60(7), pp. 985–991. Available at:
  4. Bauer, M. et al., 2021. Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 23(2), pp.180–185. Available at:
  5. Bauer, M. et al., 2020. Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology & Therapeutics, 109(3), pp.754–761. Available at: